 SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 GLOBE NEWSWIRE -- ALX Oncology Holdings Inc., ALX Oncology Nasdaq: ALXO a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in two upcoming investor conferences. 